LENSAR, Inc. (LNSR) Earnings
LENSAR, Inc. is expected to report next earnings on November 12, 2026 (in NaN days), with a consensus EPS estimate of $-0.05. LNSR has beaten EPS estimates in 5 of its last 12 reported quarters (average surprise +153.3% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Aug 13, 2026 | $-0.17 | $0.10 | +160.6% | $14M | -6.6% |
| May 8, 2026 | $0.18 | $1.56 | +743.2% | $13M | -6.0% |
| Mar 31, 2026 | $-0.07 | $-0.12 | -80.7% | $16M | -21.0% |
| Nov 6, 2025 | $-0.10 | $-0.31 | -210.0% | $14M | -29.5% |
| Aug 7, 2025 | $-0.08 | $-0.15 | -87.5% | $14M | -21.5% |
| May 8, 2025 | $-0.15 | $-2.32 | -1446.7% | $14M | +5.7% |
| Feb 27, 2025 | $-0.18 | $-1.61 | -794.4% | $17M | +19.5% |
| Nov 7, 2024 | $-0.29 | $-0.13 | +55.2% | $14M | -9.4% |
| May 9, 2024 | $-0.28 | $-0.19 | +32.1% | $11M | +0.4% |
| Mar 4, 2024 | $-0.22 | $-0.35 | -59.1% | $12M | +0.9% |
| Nov 9, 2023 | $-0.34 | $-0.23 | +32.4% | $10M | -18.4% |
| May 15, 2023 | $-0.27 | $-0.40 | -48.1% | $8M | -9.3% |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q2 FY2026 · August 13, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
- Post-Merger Reset and Strategic Direction * The proposed merger with Alcon was terminated at the end of Q1 2026, and Lensar has returned to independent operation, successfully resetting its business in Q2 2026 * Management's long-term priorities are to rebuild commercial momentum, expand the installed base of Ally systems, increase system utilization, grow high-margin recurring revenue, and strengthen surgeon relationships globally * Core strategy remains unchanged: expand installed base, provide best-in-class training/education/service to drive utilization, and scale recurring revenue - Operational Milestones * U.S. procedural market share increased to 24.1% in Q2 2026, up from 23.4% in Q1 2026 and 21.4% in Q2 2025, driven by installed base growth, higher utilization, and new installations in previously non-laser cataract surgery practices * 10 Ally systems placed in Q2, up from 7 in Q1, with 13 Ally systems remaining in backlog; Ally now accounts for nearly half of the company's global installed base, a key adoption milestone * Lensar performed 31% more procedures per installed Ally system than the national average cited by MarketScope, demonstrating strong utilization performance * The company will have its first direct presence at the European ESCRS conference in Q3 2026 to increase surgeon education and build demand for the Ally system in the region - Financial Performance Highlights * Reported GAAP net income of $3.5 million in Q2 2026, compared to a GAAP net loss of $1.8 million in Q2 2025 * Adjusted EBITDA hit a record $3.6 million, the strongest quarterly performance in company history * Reported gross margin of 59% (52% excluding a $1.1 million one-time tariff refund benefit), up from 50% in Q2 2025; margin improvement reflects higher revenue and a larger share of high-margin recurring revenue * SG&A expenses declined significantly year-over-year to $6.1 million due to the absence of $4.2 million in prior-year merger-related costs * Ended Q2 with $13.6 million in cash and cash equivalents, with Q2 operating cash flow essentially breakeven as positive adjusted EBITDA was offset by working capital and inventory investments to support future growth
Guidance
- Management expects operating expenses to increase modestly over coming quarters, returning to historical levels as the company increases strategic investment in commercial operations to support growth - Net income and adjusted EBITDA are expected to see some variability over the next several quarters as operating expenses normalize after the post-merger reset - Historically, Q3 cataract procedure volumes are the lowest of the year due to extended holidays and summer vacations across key markets, and this seasonal trend is expected to hold for 2026 - The rebuild of outside-the-U.S. distributor relationships, paused during merger negotiations, is a multi-quarter process, with updates expected after the Q3 2026 ESCRS conference
Segment performance
Lensar's business is structured around system sales and recurring revenue from procedure use of its Ally laser cataract surgery systems. Total Q2 2026 revenue was $16.5 million, representing 18% year-over-year growth. Recurring revenue, which makes up 83% of total revenue, grew 20% year-over-year to $13.7 million. Within recurring revenue, procedure revenue grew 23% year-over-year to $10.2 million on total procedure volume of 58,682 procedures, a 13% year-over-year increase. System sales revenue (non-recurring) was $2.8 million, with 10 new Ally systems placed during the quarter, growing the global Ally installed base to 215 units (30% year-over-year growth) and total global installed base (including legacy systems) to 445 units (9% year-over-year growth).
Risks & headwinds
- The termination of the Alcon merger created operational uncertainty and paused outside-the-U.S. distributor development activities, which will take multiple quarters to fully restart and rebuild - Q3 seasonal trends will likely result in lower procedure volumes relative to other quarters - U.S. new facility construction delays have pushed out timelines for some backlogged Ally system installations, creating uncertainty around near-term placement timing - New Ally installations in previously non-laser cataract surgery (femto-naive) practices require a 60-90 day ramp-up period before reaching full procedure volume, which can create near-term variability in revenue growth - Forward-looking financial and operating results are subject to unknown risks and uncertainties that could cause actual performance to differ materially from stated expectations, as detailed in the company's SEC filings
Analyst Q&A
Q: An analyst asks for details on the 13-unit Ally backlog, including geographic split and how it impacts Q3/Q4 placement expectations. /
A: Backlog is split between outside-the-U.S. orders expected to deliver in Q4 (aligned with regional holiday season timing) and U.S. orders. Several U.S. backlogged systems are delayed due to new facility construction, so near-term placement timing for those units remains unclear. No granular breakdown of sold vs. pending sales was provided.
Q: An analyst asks if the upward trend in average selling price (ASP) per procedure will continue going forward. /
A: ASP is expected to stay relatively steady with only modest incremental upside. Higher-margin U.S. procedures, which carry a higher ASP than distributor-sold outside-the-U.S. procedures, will grow as a share of total volume, pushing up aggregate ASP slightly. Legacy system replacement with Ally will ramp revenue faster for those accounts, but these are lower-volume facilities overall, creating a mixed impact on ASP.
Q: An analyst asks for an update on re-building outside-the-U.S. distributor relationships paused during the merger process. /
A: Rebuilding distributor relationships remains ongoing work in progress, and management expects it to take several quarters to fully restore activity. The upcoming ESCRS conference in Europe will include key distributor and stakeholder meetings, with updates expected after the event.
Q: An analyst asks about the trend of Ally system pricing and whether pricing will remain stable going forward. /
A: Base Ally system pricing is expected to stay relatively flat. Pricing varies slightly based on order volume (large purchases from private equity group practice owners get modest volume discounts) and distribution channel (U.S. direct sales have slightly higher pricing than distributor outside-the-U.S. sales), but these variances are not material. Procedure pricing follows volume-based tiering that creates minor quarterly fluctuations based on total account volume, with no structural changes expected.